Episode 40 of the Coworking Chronicles has us traveling to visit The Engine, Part 6…
The Engine is an incubator & accelerator supporting Tough Tech, the transformational science and engineering that solves the world’s most important challenges.
We caught up with Parisa Farzam, Ph.D. from Oxyverse, Daniel Montoro from TenSixty Biosciences, and Prakash Rao, Ph.D MBA & Mike Neil from BioVergence on this segment..
🏗️ What are they building? 🏗️
🧠 Oxyverse is building a wearable brain monitor for patients with neurocritical conditions. Their device gives clinicians real-time information about brain health so they can intervene in scenarios where every second matters.
💊 TenSixty Biosciences is developing next-gen antibody-drug conjugates (ADCs) for difficult-to-treat cancers. Their platform identifies targets that others don’t see, then turns those into new drugs
📈 BioVergence is rethinking how biotech startups get funded. Instead of investing at the company level, their model lets investors focus capital on a specific asset within a company, avoiding dilution across a broader portfolio
🤝 How can the Boston ecosystem help and who have they learned from? 🤝
🧠 Parisa Farzam, Ph.D. at Oxyverse is now working with clinicians to launch pilots after strong preliminary data. In Parisa’s words “Brain death is silent, we sound the alarm!”
She’s watching Polyose Bio, an Engine company converting food waste into high-demand polymers.
💊 Daniel Montoro at TenSixty Biosciences is in late preclinical development with strong in-vitro data and is focused on bringing together the right partners and capital to move into the clinic.
ImmunoGen, Inc., which spent 30 years struggling through the right parameters to make this entire drug class work, has influenced him the most!
📈 Prakash Rao, Ph.D MBA & Mike Neil at BioVergence are setting up operations in Switzerland this year and building both the investor base and asset pipeline globally, with a particular focus on late preclinical and Phase I companies where milestones can be monetized faster.
They’re watching AI-based drug discovery companies, both in Boston and globally, that are making it easier to identify promising assets faster.
Awesome visit to The Engine. Thanks to their team – Emily Knight, Katherine Otway Londergan & Rachael Faust – and all our participants.
Tough Tech in Boston is in GREAT hands! And we’re just getting started covering it at MGMT Boston!